Rafferty Asset Management, LLC Rigel Pharmaceuticals Inc Transaction History

Rafferty Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.67 - $3.19 $496,011 - $2.36 Million	740,315 Added 212.59%	1,088,543 $1.23 Million
Q1 2022 May 13, 2022	SELL	$2.22 - $3.45 $306,499 - $476,317	-138,063 Reduced 28.39%	348,228 $1.04 Million
Q4 2021 Feb 10, 2022	BUY	$2.36 - $3.57 $450,276 - $681,138	190,795 Added 64.57%	486,291 $1.29 Million
Q3 2021 Nov 10, 2021	SELL	$3.5 - $4.5 $408,030 - $524,610	-116,580 Reduced 28.29%	295,496 $1.07 Million
Q2 2021 Aug 10, 2021	SELL	$3.09 - $4.54 $659,270 - $968,636	-213,356 Reduced 34.11%	412,076 $1.79 Million
Q1 2021 May 10, 2021	BUY	$3.35 - $4.93 $1.8 Million - $2.64 Million	536,372 Added 602.26%	625,432 $2.14 Million
Q4 2020 Feb 10, 2021	SELL	$2.35 - $3.74 $426,933 - $679,460	-181,674 Reduced 67.1%	89,060 $312,000
Q3 2020 Nov 13, 2020	BUY	$1.78 - $4.13 $481,906 - $1.12 Million	270,734 New	270,734 $650,000
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $461,573 - $741,915	-283,174 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$2.02 - $2.61 $138,422 - $178,852	-68,526 Reduced 19.48%	283,174 $739,000
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $703,400 - $932,005	351,700 New	351,700 $904,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.